(Reuters) - Eli Lilly and Co said on Monday that its top-selling diabetes drug Trulicity significantly reduced the risk of heart attack, stroke and heart-related death in a broad range of people ...

Eli Lilly and Company’s LLY phase III study evaluating higher doses of its GLP-1 receptor agonist, Trulicity, demonstrated superiority in A1C (a measure of blood glucose) reduction in type II ...

Eli Lilly's top-launching new meds Trulicity and Taltz didn't deliver as expected in the first quarter, and executives faced a grilling Tuesday on what they plan to do about it. Market-watchers ...

Eli Lilly and Co. has the dubious distinction of receiving the first untitled letter in 2022 from the FDA’s Office of Prescription Drug Promotion. The letter, sent Jan. 19 and posted this week, takes ...

Eli Lilly and Company (LLY) announced that the FDA granted approval to two higher doses, 3 mg and 4.5 mg, of its GLP-1 receptor agonist, Trulicity. The approval was based on data from the AWARD-11 ...

Lilly began its HCP marketing push for Trulicity last year, first targeting endocrinologists in November and then primary care providers in February. The drugmaker spent $5.49 million on professional ...

Trulicity’s performance was a big positive for Lilly however, as there had been speculation that it might start to slow down thanks to the challenge from Ozempic – which has outperformed it in ...

Trulicity’s performance was a big positive for Lilly however, as there had been speculation that it might start to slow down thanks to the challenge from Ozempic – which has outperformed it in ...

Eli Lilly & Co. rolled out its weekly GLP-1 drug Trulicity in late 2014, looking to challenge Novo Nordisk’s ($NVO) daily Victoza, which had dominated that market ...

(Reuters) - Eli Lilly and Co third-quarter sales missed Wall Street estimates on Wednesday as rebates limited revenue from its top-selling diabetes drug Trulicity, and its shares fell about 4%.

Patent losses put a dent in Eli Lilly’s fourth-quarter and year-end sales ... s earnings call that professional outreach has focused on specialists until now and that the firm had just kicked off its ...